Dynamic Technology Lab Private Ltd Purchases Shares of 13,740 Guardant Health, Inc. (NASDAQ:GH)

Dynamic Technology Lab Private Ltd acquired a new position in shares of Guardant Health, Inc. (NASDAQ:GH) in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 13,740 shares of the company’s stock, valued at approximately $420,000.

Other hedge funds have also made changes to their positions in the company. Trexquant Investment LP grew its position in shares of Guardant Health by 4.1% in the 4th quarter. Trexquant Investment LP now owns 474,171 shares of the company’s stock valued at $14,486,000 after buying an additional 18,461 shares during the last quarter. California Public Employees Retirement System boosted its position in shares of Guardant Health by 13.8% in the 4th quarter. California Public Employees Retirement System now owns 178,470 shares of the company’s stock valued at $5,452,000 after purchasing an additional 21,674 shares during the period. Norges Bank purchased a new position in Guardant Health during the 4th quarter worth approximately $36,438,000. NEOS Investment Management LLC increased its position in Guardant Health by 10.9% during the fourth quarter. NEOS Investment Management LLC now owns 36,120 shares of the company’s stock worth $1,103,000 after buying an additional 3,553 shares during the period. Finally, Artisan Partners Limited Partnership purchased a new stake in Guardant Health in the fourth quarter valued at approximately $1,499,000. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Guardant Health Stock Performance

Guardant Health stock opened at $39.81 on Wednesday. Guardant Health, Inc. has a fifty-two week low of $15.81 and a fifty-two week high of $50.89. The firm has a market capitalization of $4.91 billion, a price-to-earnings ratio of -11.18 and a beta of 1.45. The stock’s fifty day moving average is $43.96 and its two-hundred day moving average is $35.21.

Guardant Health (NASDAQ:GH) last issued its quarterly earnings data on Thursday, February 20th. The company reported ($0.90) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.15). The business had revenue of $201.81 million during the quarter, compared to analyst estimates of $192.50 million. Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. As a group, sell-side analysts forecast that Guardant Health, Inc. will post -2.9 EPS for the current fiscal year.

Wall Street Analyst Weigh In

GH has been the subject of several research reports. Scotiabank upped their price target on shares of Guardant Health from $47.00 to $52.00 and gave the company a “sector outperform” rating in a research report on Monday, February 24th. Barclays began coverage on shares of Guardant Health in a research note on Thursday, January 23rd. They set an “overweight” rating and a $60.00 target price for the company. Piper Sandler boosted their price target on Guardant Health from $34.00 to $50.00 and gave the company an “overweight” rating in a research report on Wednesday, February 26th. The Goldman Sachs Group increased their price objective on Guardant Health from $49.00 to $56.00 and gave the stock a “buy” rating in a research report on Friday, February 21st. Finally, Stephens reissued an “overweight” rating and issued a $55.00 target price on shares of Guardant Health in a report on Wednesday, March 26th. Twenty equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $48.95.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.